Cargando…

Selenium and Lung Cancer: A Systematic Review and Meta Analysis

BACKGROUND: Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Fritz, Heidi, Kennedy, Deborah, Fergusson, Dean, Fernandes, Rochelle, Cooley, Kieran, Seely, Andrew, Sagar, Stephen, Wong, Raimond, Seely, Dugald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208545/
https://www.ncbi.nlm.nih.gov/pubmed/22073154
http://dx.doi.org/10.1371/journal.pone.0026259
_version_ 1782215628308873216
author Fritz, Heidi
Kennedy, Deborah
Fergusson, Dean
Fernandes, Rochelle
Cooley, Kieran
Seely, Andrew
Sagar, Stephen
Wong, Raimond
Seely, Dugald
author_facet Fritz, Heidi
Kennedy, Deborah
Fergusson, Dean
Fernandes, Rochelle
Cooley, Kieran
Seely, Andrew
Sagar, Stephen
Wong, Raimond
Seely, Dugald
author_sort Fritz, Heidi
collection PubMed
description BACKGROUND: Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies. METHODS AND FINDINGS: Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61–1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70–3.24); and all-cause-death, OR 0.93 (95%CI 0.79–1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy. CONCLUSIONS: Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context.
format Online
Article
Text
id pubmed-3208545
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32085452011-11-09 Selenium and Lung Cancer: A Systematic Review and Meta Analysis Fritz, Heidi Kennedy, Deborah Fergusson, Dean Fernandes, Rochelle Cooley, Kieran Seely, Andrew Sagar, Stephen Wong, Raimond Seely, Dugald PLoS One Research Article BACKGROUND: Selenium is a natural health product widely used in the treatment and prevention of lung cancers, but large chemoprevention trials have yielded conflicting results. We conducted a systematic review of selenium for lung cancers, and assessed potential interactions with conventional therapies. METHODS AND FINDINGS: Two independent reviewers searched six databases from inception to March 2009 for evidence pertaining to the safety and efficacy of selenium for lung cancers. Pubmed and EMBASE were searched to October 2009 for evidence on interactions with chemo- or radiation-therapy. In the efficacy analysis there were nine reports of five RCTs and two biomarker-based studies, 29 reports of 26 observational studies, and 41 preclinical studies. Fifteen human studies, one case report, and 36 preclinical studies were included in the interactions analysis. Based on available evidence, there appears to be a different chemopreventive effect dependent on baseline selenium status, such that selenium supplementation may reduce risk of lung cancers in populations with lower baseline selenium status (serum<106 ng/mL), but increase risk of lung cancers in those with higher selenium (≥121.6 ng/mL). Pooling data from two trials yielded no impact to odds of lung cancer, OR 0.93 (95% confidence interval 0.61–1.43); other cancers that were the primary endpoints of these trials, OR 1.51 (95%CI 0.70–3.24); and all-cause-death, OR 0.93 (95%CI 0.79–1.10). In the treatment of lung cancers, selenium may reduce cisplatin-induced nephrotoxicity and side effects associated with radiation therapy. CONCLUSIONS: Selenium may be effective for lung cancer prevention among individuals with lower selenium status, but at present should not be used as a general strategy for lung cancer prevention. Although promising, more evidence on the ability of selenium to reduce cisplatin and radiation therapy toxicity is required to ensure that therapeutic efficacy is maintained before any broad clinical recommendations can be made in this context. Public Library of Science 2011-11-04 /pmc/articles/PMC3208545/ /pubmed/22073154 http://dx.doi.org/10.1371/journal.pone.0026259 Text en Fritz et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fritz, Heidi
Kennedy, Deborah
Fergusson, Dean
Fernandes, Rochelle
Cooley, Kieran
Seely, Andrew
Sagar, Stephen
Wong, Raimond
Seely, Dugald
Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title_full Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title_fullStr Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title_full_unstemmed Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title_short Selenium and Lung Cancer: A Systematic Review and Meta Analysis
title_sort selenium and lung cancer: a systematic review and meta analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208545/
https://www.ncbi.nlm.nih.gov/pubmed/22073154
http://dx.doi.org/10.1371/journal.pone.0026259
work_keys_str_mv AT fritzheidi seleniumandlungcancerasystematicreviewandmetaanalysis
AT kennedydeborah seleniumandlungcancerasystematicreviewandmetaanalysis
AT fergussondean seleniumandlungcancerasystematicreviewandmetaanalysis
AT fernandesrochelle seleniumandlungcancerasystematicreviewandmetaanalysis
AT cooleykieran seleniumandlungcancerasystematicreviewandmetaanalysis
AT seelyandrew seleniumandlungcancerasystematicreviewandmetaanalysis
AT sagarstephen seleniumandlungcancerasystematicreviewandmetaanalysis
AT wongraimond seleniumandlungcancerasystematicreviewandmetaanalysis
AT seelydugald seleniumandlungcancerasystematicreviewandmetaanalysis